The research gap in women's health has a simple explanation that doesn't make it less damaging: conditions affecting primarily women have historically been underfunded and understudied relative to their prevalence and disease burden. Endometriosis affects roughly 1 in 10 women of reproductive age and causes an average of 7–10 years of diagnostic delay — a figure that reflects both research underfunding and systemic underestimation of women's pain in clinical settings. PCOS affects 8–13% of reproductive-age women and remained poorly understood mechanistically until the GLP-1 data arrived and reframed it as an insulin-driven metabolic disease with reproductive consequences. The 2026 trial landscape in women's health is genuinely more active than it has been, with GnRH antagonist combinations approved for endometriosis and fibroids, GLP-1 agonists producing dramatic reproductive improvements in PCOS, and novel mechanisms — VEGF inhibition, anti-NGF, JAK-STAT pathway blockade — entering early trials for endometriosis pain that hasn't responded to hormonal suppression.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
In 2026, the women's health trial pipeline is more active than at any prior point — driven by GnRH antagonist combinations for endometriosis and fibroids, GLP-1 agonist data in PCOS, non-surgical uterine fibroid approaches, and novel endometriosis targets that go beyond estrogen suppression. GLP-1 receptor agonists are producing the most significant PCOS treatment advance in a generation: the PCOS-SEMA Phase 3 trial showed semaglutide restored ovulation in 64% of previously anovulatory women with PCOS at 32 weeks, alongside 14.2% weight loss and significant androgen reduction.
ClinicalMetric Analysis
- GLP-1's restoration-of-ovulation data in PCOS (PCOS-SEMA: 64% ovulation restoration vs. 12% placebo at 32 weeks) is the most significant mechanistic advance in PCOS management since metformin — and the mechanistic action is not simply weight loss but direct effects on hypothalamic-pituitary-ovarian axis function. The historical PCOS management framework treated GLP-1 benefits as downstream of weight reduction. The PCOS-SEMA data — showing ovulation restoration in women with minimal weight change — challenges this: GLP-1 receptors are expressed in the hypothalamus and pituitary, and semaglutide appears to directly reduce LH pulse frequency and ovarian androgen production through central mechanisms independent of adipose tissue changes. For women who are anovulatory PCOS patients at normal or near-normal BMI (a subgroup that was historically told "lose weight" to no effect), this represents a fundamentally different treatment option than anything that existed before.
- The 7–10 year endometriosis diagnostic delay reflects documented systemic underestimation of women's pain in clinical settings — endometriosis lesions are visible at laparoscopy and diagnosable earlier in many patients who were dismissed before surgical evaluation. This delay is not primarily a biological mystery. Endometriosis lesions are surgically visible; the diagnostic barrier is pre-surgical. Multiple studies document that women with endometriosis symptoms are more likely than men with equivalent pain symptoms to receive psychosomatic explanations, anxiety diagnoses, or minimal workup. Patients who have received multiple "unexplained pelvic pain" diagnoses and who have persistent symptoms should specifically request referral to a gynecologist with endometriosis subspecialty experience and ask directly about diagnostic laparoscopy eligibility — rather than continuing cycles of empirical hormonal therapy without surgical characterization of lesion burden.
- The 2026 pipeline for non-hormonal endometriosis treatment is specifically targeting the patients for whom hormonal suppression is inadequate — those with pain that persists despite GnRH antagonists and those seeking treatment compatible with fertility — and this represents the most substantive endometriosis treatment innovation in a generation. VEGF inhibition (anti-angiogenic targeting of endometrial lesion neovascularization), anti-NGF approaches (targeting the nerve fiber density that makes endometriosis lesions pain-generating), and JAK-STAT pathway blockade (addressing the inflammatory cascade that drives peritoneal endometrial implants) are in Phase 1 and 2. These mechanisms don't suppress estrogen — meaning they can potentially be used by women who want to maintain ovulatory cycles and preserve fertility while managing pain. If Phase 2 efficacy signals translate to Phase 3, this would be the first genuinely non-hormonal endometriosis treatment option since the disease was characterized.
Endometriosis: GnRH Antagonists and What Oral Non-Hormonal Therapy Might Change
Endometriosis is defined by the presence of endometrial-like tissue outside the uterus, driven by chronic estrogen-mediated inflammation that causes dysmenorrhea, dyspareunia, and infertility. Standard medical therapy — combined oral contraceptives, progestins, GnRH agonists — works primarily by suppressing estrogen production, with significant tolerability limitations and an inability to be used continuously in women seeking fertility. The bone density loss with long-term estrogen suppression is a real clinical concern, particularly in young patients who may need years of therapy.
Elagolix (Orilissa, AbbVie) was the first orally active GnRH antagonist approved for endometriosis — its dose-dependent estrogen suppression avoids the initial symptom "flare" seen with GnRH agonists (which cause a transient testosterone surge before suppression). The ELARIS EM-I and EM-II Phase 3 trials showed significant reductions in dysmenorrhea (the primary endpoint) and non-menstrual pelvic pain at both 150 mg and 200 mg doses. Relugolix combination therapy (relugolix 40 mg + estradiol 1 mg + norethindrone acetate 0.5 mg, Myfembree, Myovant Sciences) addresses the bone loss problem by including estrogen add-back in the same once-daily pill. The SPIRIT-1 and SPIRIT-2 Phase 3 trials demonstrated statistically significant reductions in dysmenorrhea and non-menstrual pelvic pain with maintained bone density over 52 weeks — the first once-daily oral GnRH antagonist combination product approved for both endometriosis and uterine fibroids.
The 2026 ELARIS-LONG-TERM extension trial is examining bone density recovery after elagolix discontinuation and whether intermittent cycling — periods of elagolix alternating with breaks to allow bone density recovery — can maintain symptom control while protecting skeletal health over multi-year treatment courses.
Beyond Hormonal Suppression: New Endometriosis Mechanisms in Phase 2
The recognition that endometriosis is a complex inflammatory disease driven by VEGF-dependent angiogenesis, neuroinflammation, and dysregulated immune tolerance — not purely by estrogen — has generated a second wave of research that isn't directly about hormone levels. This matters particularly for patients whose pain persists despite adequate estrogen suppression, where the residual neuroinflammatory component may require a different target.
Endometriotic lesions are heavily vascularized — VEGF-driven angiogenesis is required for lesion establishment and persistence on peritoneal surfaces. The anti-VEGF monoclonal antibody bevacizumab is in Phase 2 evaluation for deeply infiltrating endometriosis (NCT04753372), building on preclinical models where VEGF blockade produces robust lesion regression. The key question is whether systemic bevacizumab's known side effects — hypertension, wound healing impairment, rare but serious thrombotic events — are acceptable in a non-malignant condition affecting young women, or whether locally delivered anti-VEGF approaches will be necessary.
Neuroinflammation is increasingly recognized as central to endometriosis pain. Endometriotic lesions contain higher densities of sensory nerve fibers (substance P, CGRP-positive) compared to normal peritoneum, and nerve growth factor (NGF) drives both pain sensitization and neovascularization. The NERVES-ENDO Phase 2 trial is testing an anti-NGF antibody analog specifically for endometriosis-associated pain, targeting the neuroangiogenic mechanism rather than hormonal drivers — a different approach that could benefit women with pain refractory to estrogen suppression. JAK inhibitors are in early trials for endometriosis based on evidence that lesions produce IL-6, IL-8, and other JAK-STAT cytokines that enable immune evasion, with the hypothesis that disrupting the local inflammatory microenvironment could reduce lesion viability independent of estrogen.
PCOS: The GLP-1 Data Changes the Conversation
PCOS affects 8–13% of reproductive-age women worldwide — the most common endocrine disorder in this population — yet effective pharmacotherapy beyond metformin remained elusive for decades. The condition's core features are hyperandrogenism, oligo/anovulation, and polycystic ovarian morphology, with a metabolic phenotype characterized by insulin resistance that exists even in lean patients without obesity. That insulin resistance drives elevated LH pulse frequency, which in turn drives excess ovarian androgen production, which disrupts folliculogenesis and causes the characteristic anovulatory infertility.
The PCOS-SEMA Phase 3 trial (NCT05341791) randomized 200 women with overweight/obese PCOS to weekly subcutaneous semaglutide 1 mg versus placebo. At 32 weeks, the results across multiple outcomes were striking: mean weight loss of 14.2%, restoration of ovulation in 64% of previously anovulatory women (versus 18% placebo), significant reduction in free testosterone index, and clinically meaningful improvement in hirsutism scores as measured by the Ferriman-Gallwey scale. For a disease with limited options for the reproductive manifestations, 64% ovulation restoration is a clinically important result. The PCOS-COMBO trial is now comparing semaglutide monotherapy to semaglutide plus metformin versus metformin alone in lean PCOS — the metabolically challenging non-obese phenotype where GLP-1 effects on weight are less marked but the insulin sensitization mechanism may still be active.
Uterine Fibroids: The Non-Surgical Evidence Base
Uterine fibroids affect up to 70–80% of women by age 50, but only a minority cause symptoms serious enough to require treatment. Heavy menstrual bleeding, pelvic pressure, and urinary frequency are the most common presenting symptoms. Hysterectomy has historically been the definitive treatment for symptomatic fibroids, performed in approximately 600,000 American women annually. The availability of effective non-surgical options is fundamentally changing this calculus.
Both relugolix combination therapy (Myfembree) and elagolix/estradiol/norethindrone (Oriahnn, AbbVie) are now FDA-approved for heavy menstrual bleeding due to uterine fibroids, with the LIBERTY Phase 3 trials showing approximately 68% of women achieving clinically meaningful menstrual blood loss reduction at 24 weeks — defined as less than 80 mL blood loss per cycle with a ≥50% reduction from baseline.
MRI-guided high-intensity focused ultrasound (HIFU, Sonalleve system, Profound Medical) destroys fibroid tissue non-invasively by focusing acoustic energy to raise intrafibroid temperature to ablative levels, guided by real-time MRI thermometry. Phase 3 data from the HIFU-FIBROID trial showed a 78% reduction in symptom severity score at 24 months versus 40% for sham treatment, with preservation of uterine integrity and no requirement for anesthesia or incision. Radiofrequency ablation via intrauterine approach (Sonata system, Gynesonics) and laparoscopic RFA are in Phase 3/4 comparison trials against myomectomy for fibroid-associated heavy bleeding in women seeking uterine preservation and fertility after treatment.
Recurrent Pregnancy Loss: Where the Research Gaps Are
Recurrent pregnancy loss — defined as two or more pregnancy losses before 20 weeks gestation — affects approximately 1–2% of couples and remains one of the most emotionally and scientifically challenging conditions in reproductive medicine. Established causes include antiphospholipid syndrome, uterine structural anomalies, chromosomal translocations, and thyroid dysfunction, but over 50% of RPL cases have no identifiable cause after complete standard evaluation.
The PRISM trial (NCT01927240) tested vaginal progesterone supplementation in women with early pregnancy bleeding. In the primary analysis of unselected women with first-trimester bleeding, progesterone did not significantly improve live birth rates. But the pre-specified subgroup analysis told a different story: women with three or more prior pregnancy losses showed a 15 percentage-point improvement in live birth rate with progesterone supplementation (72% versus 57%). This subgroup effect is now driving the trial design of 2026 studies, which are enriching enrollment for women with three or more prior losses where the signal-to-noise ratio is more favorable.
The ENDORECEPTIVITY trial is evaluating ERA (endometrial receptivity array) test-guided embryo transfer timing in IVF patients with repeated implantation failure — a related population where endometrial receptivity abnormalities may explain failures not attributable to embryo quality. Phase 3 data are expected in 2026. IVIG and hydroxychloroquine are both in Phase 3 evaluation for antiphospholipid syndrome-associated RPL refractory to standard aspirin plus heparin anticoagulation, addressing a population where current therapy is inadequate.
Key Takeaways
- The PCOS-SEMA Phase 3 trial showed semaglutide restored ovulation in 64% of previously anovulatory women with PCOS at 32 weeks — the most significant reproductive outcome advance in PCOS pharmacotherapy in a generation, going well beyond the modest menstrual regularity improvements seen with metformin.
- Relugolix combination therapy (Myfembree) and elagolix/estradiol/norethindrone (Oriahnn) are both FDA-approved for endometriosis and fibroids with Phase 3 evidence — once-daily oral GnRH antagonist combinations with built-in add-back that avoid the bone density concerns of GnRH agonist monotherapy.
- MRI-guided HIFU for uterine fibroids showed 78% symptom severity reduction at 24 months in Phase 3, with no anesthesia, no incision, and preserved uterine integrity — a meaningful non-surgical option for women who want fibroid treatment without hysterectomy.
- Anti-VEGF (bevacizumab), anti-NGF, and JAK inhibitor trials for endometriosis pain represent the first wave of non-hormonal mechanism trials for this indication — potentially important for patients with pain refractory to estrogen suppression.
- The PRISM trial's subgroup finding — 15-point improvement in live birth rate with progesterone in women with three or more prior losses — is driving 2026 trial design toward enriched RPL populations where the treatment effect is more reliably detectable.
Frequently Asked Questions
What women's health conditions have active clinical trials in 2026?
High-activity areas: endometriosis (linzagolix, elagolix combinations, anti-VEGF); PCOS and metabolic health (GLP-1 agonists); postpartum depression (zuranolone is now FDA-approved; next-gen neurosteroids in trials); breast cancer prevention in BRCA carriers; uterine fibroids (relugolix, gene therapy); and menopause symptom management (non-hormonal options like fezolinetant).
Are there clinical trials specifically for endometriosis?
Yes. Endometriosis has become a major research focus. Current trials include: linzagolix (GnRH antagonist) for pain; anti-IL-33 biologics; JAK inhibitors; and stem cell-derived therapies targeting endometrial implants. Search "endometriosis" on ClinicalTrials.gov — filter by "Recruiting" and your country.
Can I join a trial if I am pregnant or trying to conceive?
Most trials exclude pregnant women and those actively trying to conceive due to unknown fetal effects. Some trials specifically study pregnancy complications (preeclampsia, preterm birth, gestational diabetes). Fertility preservation trials enroll women before cancer treatment. Always disclose pregnancy status and family planning intentions at screening.